Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2020-11-13 Investor Presentation
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Corporate Presentation Q2 FY 21' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is a formal investor communication. The content includes company overview, investment highlights, financial performance for Q2 FY21, and strategy for future growth. It is explicitly described as a presentation for analysts and investors. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief earnings release (ER) since it contains detailed presentation slides. The document is not an announcement of a report publication but the actual presentation material itself. Therefore, the most appropriate classification is Investor Presentation (IP). The document length and detail support a high confidence score.
2020-11-13 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a compliance submission under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning Related Party Transactions for the half year ended September 30, 2020. It includes detailed disclosures of related party transactions, names of key managerial personnel, and transaction amounts. This type of document is a regulatory filing related to compliance and disclosure requirements rather than a full financial report or audit. It does not contain comprehensive financial statements or management discussion but is a specific compliance disclosure. Therefore, it fits best under Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a full annual/interim report but a detailed regulatory disclosure.
2020-11-11 English
Record Date
Regulatory Filings
2020-11-09 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges referencing Regulation 30 of SEBI Listing Regulations, which pertains to disclosure requirements. It mentions the attachment of newspaper advertisements of Unaudited Financial Results for the quarter and half year ended September 30, 2020. The document itself is short (1260 characters) and primarily serves as a notification or disclosure of the publication of financial results, not the results themselves. There is no substantive financial data or detailed financial statements included in the text. Therefore, this document is an announcement related to the publication of financial results rather than the financial report itself. According to the rules, such a document should be classified as Regulatory Filings (RNS) because it is a regulatory disclosure notice and does not contain the full financial report or detailed analysis.
2020-11-07 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investors Presentation on Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2020." It contains detailed financial data, performance highlights, management commentary, and outlook for Q2 and half-year FY21. The content is structured as a presentation intended for analysts and investors, focusing on financials, strategy, and market position. It is not a full regulatory filing like an annual or interim report, nor is it a transcript or audit report. The presence of slides, disclaimers, and forward-looking statements further supports that this is an investor presentation. Therefore, the appropriate classification is Investor Presentation (IP).
2020-11-06 English
Dividend Updates
Regulatory Filings
2020-11-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.